本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面胃癌已成为全球第五大癌症，每年的新增病例已超过 100 ...

"Roche’s VENTANA CLDN18 assay gains CE mark" was originally created and published by Medical Device Network, a GlobalData ...

If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...

Gastric cancer accounted for over one million new cases and 770,000 deaths globally in 2020, making it the sixth most common cancer worldwide ...

RxDx Assay to identify patients with gastric or GEJ cancer gets CE Mark approval: Basel Friday, October 11, 2024, ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Roche has announced the CE certification of its VENTANA CLDN18 (43-14A) RxDx Assay, marking a significant advancement in ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

The 420 mg strength of Hercessi, a biosimilar to Herceptin, is used to treat HER2-overexpressing breast and gastric or ...

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...